Tags

Type your tag names separated by a space and hit enter

I.31, a new combination of probiotics, improves irritable bowel syndrome-related quality of life.

Abstract

AIM

To determine the dose-related effects of a novel probiotic combination, I.31, on irritable bowel syndrome (IBS)-related quality of life (IBS-QoL).

METHODS

A multicenter, randomized, double-blind, placebo-controlled intervention clinical trial with three parallel arms was designed. A total of 84 patients (53 female, 31 male; age range 20-70 years) with IBS and diarrhea according to Rome-III criteria were randomly allocated to receive one capsule a day for 6 wk containing: (1) I.31 high dose (n = 28); (2) I.31 low dose (n = 27); and (3) placebo (n = 29). At baseline, and 3 and 6 wk of treatment, patients filled the IBSQoL, Visceral Sensitivity Index (VSI), and global symptom relief questionnaires.

RESULTS

During treatment, IBS-QoL increased in all groups, but this increment was significantly larger in patients treated with I.31 than in those receiving placebo (P = 0.008). After 6 wk of treatment, IBS-QoL increased by 18 ± 3 and 22 ± 4 points in the high and the low dose groups, respectively (P = 0.041 and P = 0.023 vs placebo), but only 9 ± 3 in the placebo group. Gut-specific anxiety, as measured with VSI, also showed a significantly greater improvement after 6 wk of treatment in patients treated with probiotics (by 10 ± 2 and 14 ± 2 points, high and low dose respectively, P < 0.05 for both vs 7 ± 1 score increment in placebo). Symptom relief showed no significant changes between groups. No adverse drug reactions were reported following the consumption of probiotic or placebo capsules.

CONCLUSION

A new combination of three different probiotic bacteria was superior to placebo in improving IBS-related quality of life in patients with IBS and diarrhea.

Links

  • PMC Free PDF
  • PMC Free Full Text
  • FREE Publisher Full Text
  • Authors+Show Affiliations

    ,

    Vicente Lorenzo-Zúñiga, Jordi Serra, Gastroenterology, Motility and Functional Gut Disorders Unit, Hospital Universitari Germans Trias i Pujol/CIBERehd, 08916 Badalona, Spain.

    ,

    Vicente Lorenzo-Zúñiga, Jordi Serra, Gastroenterology, Motility and Functional Gut Disorders Unit, Hospital Universitari Germans Trias i Pujol/CIBERehd, 08916 Badalona, Spain.

    ,

    Vicente Lorenzo-Zúñiga, Jordi Serra, Gastroenterology, Motility and Functional Gut Disorders Unit, Hospital Universitari Germans Trias i Pujol/CIBERehd, 08916 Badalona, Spain.

    ,

    Vicente Lorenzo-Zúñiga, Jordi Serra, Gastroenterology, Motility and Functional Gut Disorders Unit, Hospital Universitari Germans Trias i Pujol/CIBERehd, 08916 Badalona, Spain.

    ,

    Vicente Lorenzo-Zúñiga, Jordi Serra, Gastroenterology, Motility and Functional Gut Disorders Unit, Hospital Universitari Germans Trias i Pujol/CIBERehd, 08916 Badalona, Spain.

    ,

    Vicente Lorenzo-Zúñiga, Jordi Serra, Gastroenterology, Motility and Functional Gut Disorders Unit, Hospital Universitari Germans Trias i Pujol/CIBERehd, 08916 Badalona, Spain.

    Vicente Lorenzo-Zúñiga, Jordi Serra, Gastroenterology, Motility and Functional Gut Disorders Unit, Hospital Universitari Germans Trias i Pujol/CIBERehd, 08916 Badalona, Spain.

    Source

    World journal of gastroenterology 20:26 2014 Jul 14 pg 8709-16

    MeSH

    Adult
    Aged
    Diarrhea
    Double-Blind Method
    Female
    Humans
    Intestines
    Irritable Bowel Syndrome
    Lactobacillus plantarum
    Male
    Middle Aged
    Pediococcus
    Probiotics
    Quality of Life
    Spain
    Surveys and Questionnaires
    Time Factors
    Treatment Outcome
    Young Adult

    Pub Type(s)

    Journal Article
    Multicenter Study
    Randomized Controlled Trial
    Research Support, Non-U.S. Gov't

    Language

    eng

    PubMed ID

    25024629

    Citation

    Lorenzo-Zúñiga, Vicente, et al. "I.31, a New Combination of Probiotics, Improves Irritable Bowel Syndrome-related Quality of Life." World Journal of Gastroenterology, vol. 20, no. 26, 2014, pp. 8709-16.
    Lorenzo-Zúñiga V, Llop E, Suárez C, et al. I.31, a new combination of probiotics, improves irritable bowel syndrome-related quality of life. World J Gastroenterol. 2014;20(26):8709-16.
    Lorenzo-Zúñiga, V., Llop, E., Suárez, C., Alvarez, B., Abreu, L., Espadaler, J., & Serra, J. (2014). I.31, a new combination of probiotics, improves irritable bowel syndrome-related quality of life. World Journal of Gastroenterology, 20(26), pp. 8709-16. doi:10.3748/wjg.v20.i26.8709.
    Lorenzo-Zúñiga V, et al. I.31, a New Combination of Probiotics, Improves Irritable Bowel Syndrome-related Quality of Life. World J Gastroenterol. 2014 Jul 14;20(26):8709-16. PubMed PMID: 25024629.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - I.31, a new combination of probiotics, improves irritable bowel syndrome-related quality of life. AU - Lorenzo-Zúñiga,Vicente, AU - Llop,Elba, AU - Suárez,Cristina, AU - Alvarez,Beatriz, AU - Abreu,Luis, AU - Espadaler,Jordi, AU - Serra,Jordi, PY - 2013/11/06/received PY - 2014/02/05/revised PY - 2014/03/19/accepted PY - 2014/7/16/entrez PY - 2014/7/16/pubmed PY - 2015/4/14/medline KW - Irritable bowel syndrome KW - Probiotic combination KW - Quality-of-life SP - 8709 EP - 16 JF - World journal of gastroenterology JO - World J. Gastroenterol. VL - 20 IS - 26 N2 - AIM: To determine the dose-related effects of a novel probiotic combination, I.31, on irritable bowel syndrome (IBS)-related quality of life (IBS-QoL). METHODS: A multicenter, randomized, double-blind, placebo-controlled intervention clinical trial with three parallel arms was designed. A total of 84 patients (53 female, 31 male; age range 20-70 years) with IBS and diarrhea according to Rome-III criteria were randomly allocated to receive one capsule a day for 6 wk containing: (1) I.31 high dose (n = 28); (2) I.31 low dose (n = 27); and (3) placebo (n = 29). At baseline, and 3 and 6 wk of treatment, patients filled the IBSQoL, Visceral Sensitivity Index (VSI), and global symptom relief questionnaires. RESULTS: During treatment, IBS-QoL increased in all groups, but this increment was significantly larger in patients treated with I.31 than in those receiving placebo (P = 0.008). After 6 wk of treatment, IBS-QoL increased by 18 ± 3 and 22 ± 4 points in the high and the low dose groups, respectively (P = 0.041 and P = 0.023 vs placebo), but only 9 ± 3 in the placebo group. Gut-specific anxiety, as measured with VSI, also showed a significantly greater improvement after 6 wk of treatment in patients treated with probiotics (by 10 ± 2 and 14 ± 2 points, high and low dose respectively, P < 0.05 for both vs 7 ± 1 score increment in placebo). Symptom relief showed no significant changes between groups. No adverse drug reactions were reported following the consumption of probiotic or placebo capsules. CONCLUSION: A new combination of three different probiotic bacteria was superior to placebo in improving IBS-related quality of life in patients with IBS and diarrhea. SN - 2219-2840 UR - https://www.unboundmedicine.com/medline/citation/25024629/I_31_a_new_combination_of_probiotics_improves_irritable_bowel_syndrome_related_quality_of_life_ L2 - http://www.wjgnet.com/1007-9327/full/v20/i26/8709.htm DB - PRIME DP - Unbound Medicine ER -